| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S16071 R66694 |
Christensen (Levetiracetam) (All indications) (Controls exposed to LTG), 2024 | Small for gestational age (a z-score for birth weight ≤10th percentile for gestational week, sex, and country (including newborns with congenital malformations)) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
1.12 [0.92;1.36] C excluded (control group) |
125/1,077 920/8,756 | 1,045 | 1,077 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S16037 R66567 |
Christensen (Levetiracetam) (All indications) (Controls unexposed, general population), 2024 | Small for gestational age (a z-score for birth weight ≤10th percentile for gestational week, sex, and country (including newborns with congenital malformations)) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes | 1.08 [0.89;1.32] | 125/1,077 446,267/4,467,848 | 446,392 | 1,077 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15220 R62419 |
Bromley (Levetiracetam) (Epilepsy) (Controls exposed to LTG), 2023 | Small for gestation (calculated using gender-specific scales) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.67 [0.24;1.86] C excluded (control group) |
6/70 13/106 | 19 | 70 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15219 R62406 |
Bromley (Levetiracetam) (Epilepsy) (Controls unexposed, sick), 2023 | Small for gestation (calculated using gender-specific scales) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 0.48 [0.17;1.35] C | 6/70 13/80 | 19 | 70 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12618 R47566 |
Van Marter (Levetiracetam) (Controls unexposed, disease free), 2021 | Small for gestational age (weight for gestational age <10th percentile) | at least 1st trimester | prospective cohort | unexposed, disease free excluded | Adjustment: No |
0.75 [0.26;2.19] C excluded (control group) |
6/89 9/102 | 15 | 89 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12615 R47548 |
Van Marter (Levetiracetam) (Controls unexposed, sick), 2021 | Small for gestational age (weight for gestational age <10th percentile) | at least 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 2.13 [0.11;39.98] C | 6/89 0/14 | 6 | 89 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8986 R30513 |
Aydin (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2020 | Small for gestational age (birth weight) | throughout pregnancy | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
7.00 [0.30;164.40] C excluded (control group) |
3/10 0/7 | 3 | 10 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8987 R30523 |
Aydin (Levetiracetam) (Controls unexposed, sick), 2020 | Small for gestational age (birth weight) | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No | 23.15 [1.05;509.05] C | 3/10 0/22 | 3 | 10 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9020 R30711 |
Coste (Levetiracetam) (Controls unexposed, NOS), 2020 | Small for gestational age (weight) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 1.40 [1.11;1.77] C | 82/621 167,376/1,710,441 | 167,458 | 621 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9029 R30780 |
Bank (Levetiracetam) (Mixed indications), 2017 | Small for Gestational Age birthweight (<10th percentile) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.83 [0.16;20.71] C | 1/7 3/36 | 4 | 7 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 6 studies | 1.19 [0.86;1.64] | 613,882 | 1,874 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Levetiracetam) (All indications) (Controls unexposed, general population; 2: Levetiracetam) (Epilepsy) (Controls unexposed, sick; 3: Levetiracetam) (Controls unexposed, sick; 4: Levetiracetam) (Controls unexposed, sick; 5: Levetiracetam) (Controls unexposed, NOS; 6: Levetiracetam) (Mixed indications;
Asymetry test p-value = 0.6646 (by Egger's regression)
slope=0.1261 (0.1579); intercept=0.3987 (0.8532); t=0.4673; p=0.6646
excluded 8986, 12618, 15220, 16071